Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

GlobeNewswire May 11, 2018

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire May 10, 2018

Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

GlobeNewswire May 8, 2018

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

GlobeNewswire May 7, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire May 2, 2018

Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies — Discovering Underlying Factors of Influence

GlobeNewswire April 18, 2018

Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada

GlobeNewswire April 6, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire April 3, 2018

Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire March 29, 2018

Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine

GlobeNewswire March 20, 2018

Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts

GlobeNewswire March 19, 2018

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments

GlobeNewswire March 12, 2018

Aclaris Therapeutics, Inc. to Host Earnings Call

Accesswire March 12, 2018

Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders

GlobeNewswire March 9, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2018

Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018

GlobeNewswire February 28, 2018

Aclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting

GlobeNewswire February 8, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2018

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire February 2, 2018

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

GlobeNewswire January 8, 2018